ZNF625

Across TCGA pan-cancer cohorts, ZNF625 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF625 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ZNF625 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF625 expression acts as an unfavorable survival marker.

LIHC, BRCA, and UCEC are the cancer types where ZNF625 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.011	0.784	<.001	24	view →
BRCA	OS	Median	III,IV	0.027	0.907	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZNF625–LIHC (OS)

Open the LIHC breakdown →